Y. Kato

Y. Kato, A. Tsuji, Chizuru Watanabe, 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Carrier-mediated hepatic uptake of peptidic endothelin antagonists in rats.

Y. Sugiyama, P. Meier, Y. Kato, 1999, The Journal of pharmacology and experimental therapeutics.

Characterization of Long-Lasting Oatp Inhibition by Typical Inhibitor Cyclosporine A and In Vitro-In Vivo Discrepancy in Its Drug Interaction Potential in Rats.

N. Nakamichi, Y. Masuo, Y. Kato, 2016, Journal of pharmaceutical sciences.

Role of SLC xenobiotic transporters and their regulatory mechanisms PDZ proteins in drug delivery and disposition.

Y. Kato, A. Tsuji, T. Sugiura, 2006, Journal of controlled release : official journal of the Controlled Release Society.

Primary active transport of organic anions on bile canalicular membrane in humans.

Y. Sugiyama, Y. Kato, C. Tyson, 1999, The American journal of physiology.

Carrier-mediated hepatic uptake of a novel nonrenal excretion type uric acid generation inhibitor, Y-700.

Keiko Nakamura, Y. Kato, Y. Sai, 2006, Journal of pharmaceutical sciences.

Screening of the Interaction Between Xenobiotic Transporters and PDZ Proteins

Y. Kato, Y. Sai, A. Tsuji, 2004, Pharmaceutical Research.

Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats.

Y. Sugiyama, Y. Kato, H. Suzuki, 1997, Cancer research.

Potential cholestatic activity of various therapeutic agents assessed by bile canalicular membrane vesicles isolated from rats and humans.

Y. Sugiyama, Y. Kato, C. Tyson, 2003, Drug metabolism and pharmacokinetics.

Gender Difference in the Urinary Excretion of Organic Anions in Rats

H. Kusuhara, Y. Sugiyama, P. Meier, 2002, Journal of Pharmacology and Experimental Therapeutics.

Physicochemical Parameters Responsible for the Affinity of Methotrexate Analogs for Rat Canalicular Multispecific Organic Anion Transporter (cMOAT/MRP2)

Y. Sugiyama, Y. Kato, Yong-Hae Han, 2001, Pharmaceutical Research.

Bile duct obstruction leads to increased intestinal expression of breast cancer resistance protein with reduced gastrointestinal absorption of imatinib.

H. Arakawa, N. Nakamichi, Y. Masuo, 2019, Journal of pharmaceutical sciences.

Pharmacokinetics and Hepatic Uptake of Eltrombopag, a Novel Platelet-Increasing Agent

N. Nakamichi, Y. Kato, D. Silver, 2011, Drug Metabolism and Disposition.

Kinetic analysis of the primary active transport of conjugated metabolites across the bile canalicular membrane: comparative study of S-(2,4-dinitrophenyl)-glutathione and 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl)benzothiazole glucuronide.

Y. Sugiyama, Y. Kato, H. Suzuki, 1997, The Journal of pharmacology and experimental therapeutics.

6-Hydroxyindole is an endogenous long-lasting OATP1B1 inhibitor elevated in renal failure patients.

Y. Masuo, Y. Kato, Kenji Mishiro, 2020, Drug metabolism and pharmacokinetics.

Static Model–Based Assessment of OATP1B1-Mediated Drug Interactions with Preincubation-Dependent Inhibitors Based on Inactivation and Recovery Kinetics

Y. Masuo, Y. Kato, Azusa Futatsugi, 2020, Drug Metabolism and Disposition.

Short-lasting inhibition of hepatic uptake transporter OATP1B1 by tyrosine kinase inhibitor pazopanib.

Y. Masuo, Y. Kato, T. Taguchi, 2019, Drug metabolism and pharmacokinetics.

Xenobiotic transporter-adaptor network.

Y. Kato, 2007, Drug metabolism and pharmacokinetics.

Both cMOAT/MRP2 and another unknown transporter(s) are responsible for the biliary excretion of glucuronide conjugate of the nonpeptide angiotensin II antagonist, telmisaltan.

Y. Sugiyama, Y. Kato, A. Nishino, 2000, Drug metabolism and disposition: the biological fate of chemicals.

Toxicological implications of hepatobiliary transporters.

Y. Sugiyama, Y. Kato, Hiroshi Suzuki, 2002, Toxicology.

Effects of Probenecid on Hepatic and Renal Disposition of Hexadecanedioate, an Endogenous Substrate of Organic Anion Transporting Polypeptide 1B in Rats.

Y. Masuo, Y. Kato, Azusa Futatsugi, 2021, Journal of pharmaceutical sciences.

Hepatobiliary transport governs overall elimination of peptidic endothelin antagonists in rats.

Y. Sugiyama, Y. Kato, A. Hisaka, 1999, The Journal of pharmacology and experimental therapeutics.

Transport of 3-fluoro-L-α-methyl-tyrosine (FAMT) by organic ion transporters explains renal background in [(18)F]FAMT positron emission tomography.

Y. Kanai, Y. Kato, K. Kaira, 2016, Journal of pharmacological sciences.

A Liposomal Gemcitabine, FF-10832, Improves Plasma Stability, Tumor Targeting, and Antitumor Efficacy of Gemcitabine in Pancreatic Cancer Xenograft Models

Y. Kato, M. Sakabe, Tsukasa Kitahashi, 2021, Pharmaceutical Research.

PDZ Adaptor Protein PDZK2 Stimulates Transport Activity of Organic Cation/Carnitine Transporter OCTN2 by Modulating Cell Surface Expression

Y. Kato, A. Tsuji, T. Sugiura, 2006, Drug Metabolism and Disposition.

PDZK1 Directly Regulates the Function of Organic Cation/Carnitine Transporter OCTN2

Y. Kato, Y. Sai, A. Tsuji, 2005, Molecular Pharmacology.

Organic Cation/Carnitine Transporter OCTN2 (Slc22a5) Is Responsible for Carnitine Transport across Apical Membranes of Small Intestinal Epithelial Cells in Mouse

Y. Kato, Y. Sai, I. Tamai, 2006, Molecular Pharmacology.

Involvement of carnitine/organic cation transporter OCTN2 (SLC22A5) in distribution of its substrate carnitine to the heart.

Y. Kato, Y. Sai, A. Tsuji, 2008, Drug metabolism and pharmacokinetics.

PDZK1 Regulates Two Intestinal Solute Carriers (Slc15a1 and Slc22a5) in Mice

Y. Kato, A. Tsuji, D. Silver, 2008, Drug Metabolism and Disposition.

Functional characterization of human organic cation transporter OCTN1 single nucleotide polymorphisms in the Japanese population.

Y. Kato, Y. Sai, A. Tsuji, 2004, Journal of pharmaceutical sciences.

Mutation in an adaptor protein PDZK1 affects transport activity of organic cation transporter OCTNs and oligopeptide transporter PEPT2.

Y. Kato, A. Tsuji, T. Sugiura, 2006, Drug metabolism and pharmacokinetics.

Involvement of Multidrug Resistance-Associated Protein 1 in Intestinal Toxicity of Methotrexate

Y. Kato, A. Tsuji, Y. Kubo, 2009, Pharmaceutical Research.

Food‐derived hydrophilic antioxidant ergothioneine is distributed to the brain and exerts antidepressant effect in mice

N. Nakamichi, Y. Masuo, Hirotaka Sekiguchi, 2016, Brain and behavior.

The Rab8 GTPase regulates apical protein localization in intestinal cells

A. Harada, Y. Kato, K. Ozono, 2007, Nature.

Experimental Approaches to the Study of Drug Transporters

Y. Kato, A. Tsuji, Y. Kubo, 2014 .

Ergothioneine in the brain

Y. Kato, Takahiro Ishimoto, 2022, FEBS letters.

Physiological Roles of Carnitine/Organic Cation Transporter OCTN1/SLC22A4 in Neural Cells.

N. Nakamichi, Y. Kato, 2017, Biological & pharmaceutical bulletin.

Distinct alterations in ATP-binding cassette transporter expression in liver, kidney, small intestine, and brain in adjuvant-induced arthritic rats.

Y. Kato, M. Iwaki, A. Kawase, 2014, Journal of pharmaceutical sciences.

Kinetic profile of overall elimination of 5-methyltetrahydropteroylglutamate in rats.

H. Kusuhara, Y. Sugiyama, Y. Kato, 1999, American journal of physiology. Endocrinology and metabolism.

S-Methyl-L-Ergothioneine to L-Ergothioneine Ratio in Urine Is a Marker of Cystine Lithiasis in a Cystinuria Mouse Model

Y. Kato, Virginia Nunes, A. Llebaria, 2021, Antioxidants.

Combination Metabolomics Approach for Identifying Endogenous Substrates of Carnitine/Organic Cation Transporter OCTN1

N. Nakamichi, Y. Masuo, Aya Hasan Al-Shammari, 2018, Pharmaceutical Research.

Carnitine/Organic Cation Transporter OCTN1 Negatively Regulates Activation in Murine Cultured Microglial Cells

N. Nakamichi, Y. Masuo, Y. Kato, 2018, Neurochemical Research.

Localization of Xenobiotic Transporter OCTN1/SLC22A4 in Hepatic Stellate Cells and Its Protective Role in Liver Fibrosis.

S. Kaneko, N. Nakamichi, Y. Masuo, 2016, Journal of pharmaceutical sciences.

Functional expression of carnitine/organic cation transporter OCTN1 in mouse brain neurons: Possible involvement in neuronal differentiation

N. Nakamichi, Y. Kato, T. Sugiura, 2012, Neurochemistry International.

Gene Knockout and Metabolome Analysis of Carnitine/Organic Cation Transporter OCTN1

M. Tomita, T. Matsui, S. Kaneko, 2010, Pharmaceutical Research.

Title Site-dependent contributions of P-glycoprotein and CYP 3 A to cyclosporinA absorption , and effect of dexamethasone in small intestine of mice

T. Shimada, K. Miyamoto, Y. Kato, 2017 .

Functional Expression of Carnitine/Organic Cation Transporter OCTN1/SLC22A4 in Mouse Small Intestine and Liver

T. Soga, Kazuhiro Suzuki, N. Nakamichi, 2010, Drug Metabolism and Disposition.

Anti-metastatic effect of the sialyl Lewis-X analog GSC-150 on the human colon carcinoma derived cell line KM12-HX in the mouse.

Y. Sugiyama, T. Irimura, Y. Kato, 2001, Biological & pharmaceutical bulletin.

Recent Insights into Human Endometrial Peptidases in Blastocyst Implantation via Shedding of Microvesicles

S. Mizutani, Y. Kato, Kunio Matsumoto, 2021, International journal of molecular sciences.

Organic cation transporter Octn1-mediated uptake of food-derived antioxidant ergothioneine into infiltrating macrophages during intestinal inflammation in mice.

N. Nakamichi, Y. Masuo, Y. Kato, 2015, Drug metabolism and pharmacokinetics.

Carrier-mediated hepatobiliary transport of a novel antifolate, N-[4-[(2,4-dianninopteridine-6-yl)methyl]-3,4-dihydro-2H-1,4-benzothiazin-7-yl]carbonyl-L-homoglutamic acid, in rats.

Y. Sugiyama, Y. Kato, Y. H. Han, 2001, Drug metabolism and disposition: the biological fate of chemicals.

Existence of two pathways for the endocytosis of epidermal growth factor by rat liver: phenylarsine oxide-sensitive and -insensitive pathways.

Y. Sawada, Y. Kato, H. Suzuki, 1992, Proceedings of the National Academy of Sciences of the United States of America.

Preventive Effect of Salicylate and Pyridoxamine on Diabetic Nephropathy

Hiroshi Yamamoto, Yasuhiko Yamamoto, Y. Masuo, 2016, Journal of diabetes research.

Inhibition of oligopeptide transporter suppress growth of human pancreatic cancer cells.

Y. Kato, A. Tsuji, S. Nishimura, 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Screening to Identify Multidrug Resistance-Associated Protein Inhibitors with Neuroblastoma-Selective Cytotoxicity.

N. Nakamichi, Y. Masuo, Y. Kato, 2016, Biological & pharmaceutical bulletin.

High-speed SICM for the Visualization of Nanoscale Dynamic Structural Changes in Hippocampal Neurons.

Y. Korchev, Yasufumi Takahashi, N. Nakamichi, 2019, Analytical chemistry.

Multidrug Resistance—Associated Protein 1 Functions as an Efflux Pump of Xenobiotics in the Skin

T. Imai, Y. Kato, Y. Sai, 2005, Pharmaceutical Research.

Analysis of hiPSCs differentiation toward hepatocyte-like cells upon extended exposition to oncostatin.

Y. Sakai, C. Plessy, H. Arakawa, 2020, Differentiation; research in biological diversity.

Stereoselective hepatobiliary transport of the quinolone antibiotic grepafloxacin and its glucuronide in the rat.

H. Sasabe, Y. Sugiyama, Y. Kato, 1998, The Journal of pharmacology and experimental therapeutics.

Hepatobiliary transport mechanism for the cyclopentapeptide endothelin antagonist BQ-123.

Y. Sugiyama, Y. Kato, T. Yamada, 1997, The American journal of physiology.

Transporter-mediated renal handling of nafamostat mesilate.

Y. Kato, Y. Sai, I. Tamai, 2004, Journal of pharmaceutical sciences.

Human placental extract stimulates liver regeneration in rats.

Y. Sugiyama, Y. Kato, T. Kaku, 1998, Biological & pharmaceutical bulletin.

A Novel Hepatic-Targeting System for Therapeutic Cytokines That Delivers to the Hepatic Asialoglycoprotein Receptor, but Avoids Receptor-Mediated Endocytosis

Y. Sugiyama, Y. Kato, H. Sato, 2002, Pharmaceutical Research.

Targeted delivery of peptides, proteins, and genes by receptor-mediated endocytosis.

Y. Sugiyama, Y. Kato, 1997, Critical reviews in therapeutic drug carrier systems.

Efficient extraction by the liver governs overall elimination of hepatocyte growth factor in rats.

T. Nakamura, Y. Sugiyama, Y. Kato, 1999, The Journal of pharmacology and experimental therapeutics.

Importance of the liver in plasma clearance of hepatocyte growth factors in rats.

T. Nakamura, Y. Sugiyama, Y. Kato, 1992, The American journal of physiology.

Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats.

Y. Kato, K. Kumaki, H. Kamiyama, 1997, The Journal of pharmacology and experimental therapeutics.

Cationic polyrotaxanes effectively inhibit uptake via carnitine/organic cationic transporters without cytotoxicity.

Y. Kato, N. Yui, Ryo Katoono, 2008, Macromolecular bioscience.

A common missense variant of monocarboxylate transporter 9 (MCT9/SLC16A9) gene is associated with renal overload gout, but not with all gout susceptibility

N. Hamajima, K. Wakai, N. Shinomiya, 2013, Human Cell.

PDZK1 Regulates Breast Cancer Resistance Protein in Small Intestine

N. Nakamichi, Y. Kato, D. Silver, 2011, Drug Metabolism and Disposition.

Organic Cation Transporter 1 Is Responsible for Hepatocellular Uptake of the Tyrosine Kinase Inhibitor Pazopanib

H. Arakawa, N. Nakamichi, Y. Masuo, 2018, Drug Metabolism and Disposition.

Characterization of the Hepatic Disposition of Lanoteplase, a Rationally Designed Variant of Tissue Plasminogen Activator in Rodents

Y. Sugiyama, Y. Kato, Y. Hayashi, 2007, Drug Metabolism and Disposition.

variant of tissue plasminogen activator, in rodents

Y. Sugiyama, Y. Kato, Y. Hayashi, 2006 .

Heterophilic Binding of the Adhesion Molecules Poliovirus Receptor and Immunoglobulin Superfamily 4A in the Interaction Between Mouse Spermatogenic and Sertoli Cells1

Y. Kitamura, Y. Kato, Y. Sai, 2007, Biology of reproduction.

Direct evidence for efficient transport and minimal metabolism of L-cephalexin by oligopeptide transporter 1 in budded baculovirus fraction.

Y. Kato, I. Tamai, A. Tsuji, 2009, Biological & pharmaceutical bulletin.

Cancer Detection Using a PET Tracer, 11C-Glycylsarcosine, Targeted to H+/Peptide Transporter

Y. Kato, A. Tsuji, Yukio Nakamura, 2008, Journal of Nuclear Medicine.

PDZK 1 Regulates Two Intestinal Solute Carriers ( Slc 15 a 1 and Slc 22 a 5 ) in Mice

Y. Kato, A. Tsuji, D. Silver, 2008 .

Cell density-dependent mitogenic effect and -independent cellular handling of epidermal growth factor in primary cultured rat hepatocytes.

Y. Sugiyama, T. Terasaki, Y. Kato, 1997, Journal of hepatology.

Influence of Drugs and Nutrients on Transporter Gene Expression Levels in Caco-2 and LS180 Intestinal Epithelial Cell Lines

Y. Kato, Y. Sai, I. Tamai, 2003, Pharmaceutical Research.

Crosstalk between foetal vasoactive peptide hormones and placental aminopeptidases regulates placental blood flow: Its significance in preeclampsia.

H. Kajiyama, S. Mizutani, Y. Masuo, 2022, Placenta.

The endothelin receptor is a major determinant for the nonlinear tissue distribution of the endothelin antagonist BQ-123.

T. Nakamura, Y. Sugiyama, Y. Kato, 1996, The Journal of pharmacology and experimental therapeutics.

Myoglobin and the regulation of mitochondrial respiratory chain complex IV

K. Masuda, Y. Kato, T. Jue, 2016, The Journal of physiology.

Nonlinear disposition kinetics of a novel antifolate, MX-68, in rats.

Y. Sugiyama, Y. Kato, Y. H. Han, 1999, The Journal of pharmacology and experimental therapeutics.

Accurate Evaluation of Hepatocyte Metabolisms on a Noble Oxygen-Permeable Material With Low Sorption Characteristics

Y. Sakai, Y. Kato, M. Nishikawa, 2022, Frontiers in Toxicology.

Investigation of the Role of Oligopeptide Transporter PEPT1 and Sodium/Glucose Cotransporter SGLT1 in Intestinal Absorption of Their Substrates Using Small GTP-Binding Protein Rab8-Null Mice

A. Harada, Y. Kato, A. Tsuji, 2009, Drug Metabolism and Disposition.

Ligand-induced downregulation of receptor-mediated clearance of hepatocyte growth factor in rats.

Y. Sugiyama, Y. Kato, Toshikazu Nakamura, 1998, American journal of physiology. Endocrinology and metabolism.

Protamine enhances the proliferative activity of hepatocyte growth factor in rats.

Y. Sugiyama, Y. Kato, Toshikazu Nakamura, 1998, American journal of physiology. Gastrointestinal and liver physiology.

Protamine enhances the proliferative activity of hepatocyte growth factor in rats.

K. Matsumoto, T. Nakamura, Y. Sugiyama, 1998, The American journal of physiology.

Existence of two nonlinear elimination mechanisms for hepatocyte growth factor in rats.

Y. Sugiyama, Motohiro Kato, Y. Kato, 1997, American journal of physiology. Endocrinology and metabolism.

Existence of two nonlinear elimination mechanisms for hepatocyte growth factor in rats.

T. Nakamura, Y. Sugiyama, Y. Kato, 1997, The American journal of physiology.

Heparin‐hepatocyte growth factor complex with low plasma clearance and retained hepatocyte proliferating activity

T. Nakamura, Y. Sugiyama, Y. Kato, 1994, Hepatology.

Receptor-Mediated Targeting of Peptides and Proteins

Y. Sugiyama, Y. Kato, 1996 .

- 1-Muscle contraction increases carnitine uptake via translocation of OCTN 2

K. Masuda, Y. Kato, T. Sugiura, 2017 .

Muscle contraction increases carnitine uptake via translocation of OCTN2.

K. Masuda, Y. Kato, T. Sugiura, 2012, Biochemical and biophysical research communications.

Pharmacokinetic Aspects of Peptide Delivery and Targeting: Importance of Receptor-Mediated Endocytosis

Y. Sugiyama, Y. Kato, 1994 .

Physiologically based pharmacokinetic model of the DPP-4 inhibitor linagliptin to describe its nonlinear pharmacokinetics in humans.

Y. Kato, A. Sarashina, S. Tatami, 2020, Journal of pharmaceutical sciences.

Possible utility of peptide-transporter-targeting [19F]dipeptides for visualization of the biodistribution of cancers by nuclear magnetic resonance imaging.

H. Arakawa, I. Aoki, Y. Kato, 2020, International journal of pharmaceutics.

Title Involvement of multidrug resistance-associated protein 1 in intestinaltoxicity of methotrexate

Y. Kato, A. Tsuji, Y. Kubo, 2017 .

Gene Knockout and Metabolome Analysis of SLC22A4

M. Tomita, M. Sugimoto, T. Soga, 2010 .

PDZK 1 Directly Regulates the Function of Organic Cation / Carnitine Transporter OCTN 2

Y. Kato, Y. Sai, A. Tsuji, 2004 .

L-type fatty acid binding protein transgenic mouse as a novel tool to explore cytotoxicity to renal proximal tubules.

Kimihiro Ito, T. Sugaya, Y. Kato, 2008, Drug metabolism and pharmacokinetics.

Binding and transport of methotrexate and its derivative, MX‐68, across the brush‐border membrane in rat kidney

Y. Sugiyama, Y. Kato, Y. H. Han, 1999, Biopharmaceutics & drug disposition.

Hydroxyprolylserine derivatives JBP923 and JBP485 exhibit the antihepatitis activities after gastrointestinal absorption in rats.

Y. Sugiyama, Y. Kato, T. Santa, 2000, The Journal of pharmacology and experimental therapeutics.

Hydroxyprolylserine Derivatives JBP 923 and JBP 485 Exhibit the Antihepatitis Activities after Gastrointestinal Absorption in Rats 1

Y. Sugiyama, Y. Kato, T. Santa, 2000 .

Critical evaluation and methodological positioning of the transdermal microdialysis technique. A review.

N. Nakamichi, Y. Kato, F. Erdő, 2016, Journal of controlled release : official journal of the Controlled Release Society.

P-glycoprotein (Abcb1) is involved in absorptive drug transport in skin.

Yukio Kato, Akira Tsuji, Yoshiyuki Kubo, 2008, Journal of controlled release : official journal of the Controlled Release Society.

Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats.

Y. Sugiyama, X. Chu, Y. Kato, 1997, The Journal of pharmacology and experimental therapeutics.

Decrease in the hepatic clearance of hepatocyte growth factor in carbon tetrachloride–intoxicated rats

Y. Sugiyama, Y. Kato, Toshikazu Nakamura, 1993, Hepatology.

P-Glycoprotein in skin contributes to transdermal absorption of topical corticosteroids.

Yukio Kato, Yusuke Masuo, N. Nakamichi, 2017, International journal of pharmaceutics.

ATP binding cassette transporters in two distinct compartments of the skin contribute to transdermal absorption of a typical substrate.

Yukio Kato, Akira Tsuji, Tomoko Sugiura, 2013, Journal of controlled release : official journal of the Controlled Release Society.

Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice.

Y. Sugiyama, N. Nishiyama, K. Kataoka, 2003, Cancer research.

Increased Plasma Concentrations of Unbound SN-38, the Active Metabolite of Irinotecan, in Cancer Patients with Severe Renal Failure

Yukio Kato, Yusuke Masuo, Y. Masuo, 2015, Pharmaceutical Research.

Carrier-mediated uptake of grepafloxacin, a fluoroquinolone antibiotic, by the isolated rat lung cells.

H. Sasabe, Y. Sugiyama, Y. Kato, 2005, Drug metabolism and pharmacokinetics.

A Time- and Cost-Saving Method of Producing Rat Polyclonal Antibodies

Y. Kato, A. Tsuji, T. Wakayama, 2006, Acta histochemica et cytochemica.

Characterization of novel kidney-specific delivery system using an alkylglucoside vector.

Y. Sugiyama, Y. Kato, K. Suzuki, 2001, The Journal of pharmacology and experimental therapeutics.

Homostachydrine is a Xenobiotic Substrate of OCTN1/SLC22A4 and Potentially Sensitizes Pentylenetetrazole-Induced Seizures in Mice

N. Nakamichi, Y. Masuo, M. Nishiyama, 2020, Neurochemical Research.

Effect of coadministration of rifampicin on the pharmacokinetics of linezolid: clinical and animal studies

T. Shimada, H. Tsuchiya, Y. Kato, 2018, Journal of Pharmaceutical Health Care and Sciences.

Involvement of carnitine/organic cation transporter OCTN1/SLC22A4 in gastrointestinal absorption of metformin.

H. Kusuhara, Y. Sugiyama, K. Miyamoto, 2013, Journal of pharmaceutical sciences.

[Possible Treatment of Neuropsychiatric Disorders by Promotion of Neuronal Differentiation through Organic Cation Transporters].

N. Nakamichi, Y. Masuo, Y. Kato, 2019, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

Combination Metabolomics Approach for Identifying Endogenous Substrates of Carnitine/Organic Cation Transporter OCTN1

N. Nakamichi, Y. Masuo, Aya Hasan Al-Shammari, 2018, Pharmaceutical Research.

L503F variant of carnitine/organic cation transporter 1 efficiently transports metformin and other biguanides

N. Nakamichi, Y. Masuo, Y. Kato, 2016, The Journal of pharmacy and pharmacology.

Dipeptide species regulate p38MAPK–Smad3 signalling to maintain chronic myelogenous leukaemia stem cells

H. Nakauchi, S. Stirdivant, A. Ooshima, 2015, Nature Communications.

Organic Cation Transporter-Mediated Ergothioneine Uptake in Mouse Neural Progenitor Cells Suppresses Proliferation and Promotes Differentiation into Neurons

N. Nakamichi, Y. Masuo, Y. Kato, 2014, PloS one.

Chronic liver disease enables gut Enterococcus faecalis colonization to promote liver carcinogenesis

M. Honda, S. Kaneko, M. Oshima, 2021, Nature Cancer.

Regulation of Neurogenesis by Organic Cation Transporters: Potential Therapeutic Implications.

Y. Kato, Takahiro Ishimoto, 2021, Handbook of experimental pharmacology.

Multi‐omics analysis of hiPSCs‐derived HLCs matured on‐chip revealed patterns typical of liver regeneration

Y. Sakai, C. Plessy, H. Arakawa, 2021, Biotechnology and bioengineering.

The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites.

Y. Sugiyama, Y. Kato, C. Tyson, 2002, Drug metabolism and pharmacokinetics.

Pdz Adaptors: Their Regulation of Epithelial Transporters and Involvement in Human Diseases Transporter-pdz Adaptor Interactions -2

Y. Kato, T. Sugiura, A. Kijima, 2022 .

Effect of knockdown of ezrin, radixin, and moesin on P-glycoprotein function in HepG2 cells.

Y. Kato, T. Ogihara, K. Morimoto, 2011, Journal of pharmaceutical sciences.

Active efflux of CPT-11 and its metabolites in human KB-derived cell lines.

Y. Sugiyama, X. Chu, S. Akiyama, 1999, The Journal of pharmacology and experimental therapeutics.

Interaction of Novel Platelet-Increasing Agent Eltrombopag with Rosuvastatin via Breast Cancer Resistance Protein in Humans

Yukio Kato, Tomoko Sugiura, Yusuke Masuo, 2014, Drug Metabolism and Disposition.

Direct Inhibition and Down-regulation by Uremic Plasma Components of Hepatic Uptake Transporter for SN-38, an Active Metabolite of Irinotecan, in Humans

N. Nakamichi, Y. Kato, Y. Sasaki, 2013, Pharmaceutical Research.

Comparative Inhibitory Effects of Different Compounds on Rat Oatp1 (Slc21a1)- and Oatp2 (Slc21a5)-Mediated Transport

T. Abe, H. Kusuhara, Y. Sugiyama, 2002, Pharmaceutical Research.

OCTN2 is associated with carnitine transport capacity of rat skeletal muscles

K. Masuda, Y. Kato, T. Sugiura, 2010, Acta physiologica.

Placental Leucine Aminopeptidase as a Potential Specific Urine Biomarker for Invasive Ovarian Cancer

H. Kajiyama, S. Mizutani, Y. Kato, 2021, Journal of clinical medicine.

Combinational therapy with antibiotics and antibiotic-loaded adipose-derived stem cells reduce abscess formation in implant-related infection in rats

H. Arakawa, N. Sugimoto, H. Tsuchiya, 2020, Scientific Reports.

Investigation of the hepatic development in the coculture of hiPSCs-derived LSECs and HLCs in a fluidic microenvironment

Y. Sakai, C. Plessy, H. Arakawa, 2021, APL bioengineering.

Long-circulating poly(ethylene glycol)-poly(D,L-lactide) block copolymer micelles with modulated surface charge.

Y. Sugiyama, K. Kataoka, Y. Kato, 2001, Journal of controlled release : official journal of the Controlled Release Society.

Involvement of an organic anion transporter (canalicular multispecific organic anion transporter/multidrug resistance-associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats.

Y. Sugiyama, Y. Kato, H. Suzuki, 2000, The Journal of pharmacology and experimental therapeutics.

Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters.

Y. Sugiyama, X. Chu, Y. Kato, 1998, Cancer research.

Decreased radixin function for ATP-binding cassette transporters in liver in adjuvant-induced arthritis rats.

Y. Kato, M. Iwaki, A. Kawase, 2014, Journal of pharmaceutical sciences.

Effect of perfusate pH on the influx of 5-5'-dimethyl-oxazolidine-2,4-dione and dissociation of epidermal growth factor from the cell-surface receptor: the existence of the proton diffusion barrier in the Disse space.

Y. Sawada, T. Iga, Y. Kato, 1994, Journal of hepatology.

Pharmacokinetics of erythropoietin in genetically anemic mice.

Y. Kato, Y Kato, Y Sugiyama, 1998, Drug metabolism and disposition: the biological fate of chemicals.

Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein

Y. Sugiyama, X. Chu, Y. Kato, 2009, Cancer Chemotherapy and Pharmacology.

Involvement of organic anion transport system in transdermal absorption of flurbiprofen.

Y. Kato, A. Tsuji, Y. Kubo, 2007, Journal of controlled release : official journal of the Controlled Release Society.

Inhibition of biliary excretion of methotrexate by probenecid in rats: quantitative prediction of interaction from in vitro data.

Y. Sugiyama, Y. Kato, Y Sugiyama, 2001, The Journal of pharmacology and experimental therapeutics.

Pharmacokinetics and Pharmacodynamics following Intravenous Administration of Recombinant Human Hepatocyte Growth Factor in Rats with Renal Injury

Y. Kato, Kunio Matsumoto, A. Yamashita, 2014, Pharmacology.

Elucidation of N 1 -methyladenosine as a Potential Surrogate Biomarker for Drug Interaction Studies Involving Renal Organic Cation Transporters s

K. Maeda, H. Kusuhara, Y. Kato, 2019 .

Primary active transport of peptidic endothelin antagonists by rat hepatic canalicular membrane.

Y. Sugiyama, Y. Kato, A. Hisaka, 1999, The Journal of pharmacology and experimental therapeutics.

Contribution of radixin to P-glycoprotein expression and transport activity in mouse small intestine in vivo.

Y. Kato, T. Ogihara, K. Yano, 2013, Journal of pharmaceutical sciences.

Functional regions of organic cation/carnitine transporter OCTN2 (SLC22A5): roles in carnitine recognition.

Y. Kato, Y. Sai, M. Ishiguro, 2004, Drug metabolism and pharmacokinetics.

Increased Plasma Concentrations of Unbound SN-38, the Active Metabolite of Irinotecan, in Cancer Patients with Severe Renal Failure

Y. Masuo, Y. Kato, Y. Sasaki, 2016, Pharmaceutical Research.

PEPT (SLC15A) Family

Y. Kato, A. Tsuji, T. Sugiura, 2013 .

Renal handling of biphosphonate alendronate in rats

Y. Sugiyama, Y. Kato, J. Lin, 1999, Biopharmaceutics & drug disposition.

A physiologically based pharmacokinetic and pharmacodynamic model for disposition of FF-10832.

Y. Masuo, Y. Kato, Tadaaki Ioroi, 2022, International journal of pharmaceutics.

Kinetic Analysis of the Disposition of Insulin-Like Growth Factor 1 in Healthy Volunteers

Y. Sugiyama, Y. Kato, A. Urae, 2001, Pharmaceutical Research.

Current Progress Toward a Better Understanding of Drug Disposition Within the Lungs: Summary Proceedings of the First Workshop on Drug Transporters in the Lungs.

Mark Gumbleton, Tetsuya Terasaki, William Couet, 2017, Journal of pharmaceutical sciences.

Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin.

H. Kusuhara, Y. Sugiyama, Y. Kato, 2003, Molecular pharmacology.

Na+/H+ exchanger 3 affects transport property of H+/oligopeptide transporter 1.

Yukio Kato, Akira Tsuji, Yoshiyuki Kubo, 2005, Drug metabolism and pharmacokinetics.

Cryopreserved human hepatocytes culture optimization on polymethylpentene oxygen permeable membranes for drug screening purposes

H. Arakawa, Y. Kato, M. Nishikawa, 2022, Fundamental Toxicological Sciences.

Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems.

Y. Sugiyama, Kiyomi Ito, Y. Kato, 2000, Drug metabolism and disposition: the biological fate of chemicals.

Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38

Y. Masuo, Y. Kato, Y. Kiuchi, 2019, Cancer Chemotherapy and Pharmacology.

Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites.

Yukio Kato, Yusuke Masuo, N. Nakamichi, 2017, Journal of pharmaceutical sciences.

Functional Expression of Stereoselective Metabolism of Cephalexin by Exogenous Transfection of Oligopeptide Transporter PEPT1

Y. Kato, A. Tsuji, Y. Kubo, 2007, Drug Metabolism and Disposition.

A common missense variant of monocarboxylate transporter 9 (MCT9/SLC16A9) gene is associated with renal overload gout, but not with all gout susceptibility

N. Hamajima, K. Wakai, N. Shinomiya, 2013, Human Cell.

Title Pdz adaptors : Their regulation of epithelial transporters and involvement inhuman diseases

Y. Kato, T. Sugiura, A. Kijima, 2017 .

Effects of Osthol Isolated from Cnidium monnieri Fruit on Urate Transporter 1

Y. Kato, T. Makino, T. Takada, 2018, Molecules.

Utilization of Liver Microsomes to Estimate Hepatic Intrinsic Clearance of Monoamine Oxidase Substrate Drugs in Humans

Y. Kanai, N. Nakamichi, Y. Masuo, 2017, Pharmaceutical Research.

Maturational Characterization of Mouse Cortical Neurons Three-Dimensionally Cultured in Functional Polymer FP001-Containing Medium.

N. Nakamichi, Y. Masuo, Y. Kato, 2019, Biological & pharmaceutical bulletin.

Asymmetric Intestinal First-Pass Metabolism Causes Minimal Oral Bioavailability of Midazolam in Cynomolgus Monkey

Y. Kato, A. Tsuji, N. Amano, 2007, Drug Metabolism and Disposition.

BILIARY EXCRETION MECHANISM OF IRINOTECAN CPT-1 1 AND ITS METABOLITES IN HUMANS AND RATS: INVOLVEMENT OF cMOAT and P-gp

Y. Sugiyama, X. Chu, Y. Kato, 1998 .

Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol.

Y. Kato, A. Tsuji, T. Sugiura, 2009, Journal of pharmaceutical sciences.

Effect of coadministration of rifampicin on the pharmacokinetics of linezolid: clinical and animal studies

T. Shimada, H. Tsuchiya, Y. Kato, 2018, Journal of Pharmaceutical Health Care and Sciences.

GLYCOPROTEIN BY VALSPODAR IN GENE TRANSFECTANT SYSTEMS

Y. Sugiyama, Kiyomi Ito, Y. Kato, 2000 .

Adeno-associated virus-mediated knockdown demonstrates the major role of hepatic Bcrp in the overall disposition of the active metabolite of the tyrosine kinase inhibitor regorafenib in mice.

Y. Masuo, Y. Kato, K. Fujita, 2022, Drug metabolism and pharmacokinetics.

Oral administration of the food derived hydrophilic antioxidant ergothioneine enhances object recognition memory in mice.

N. Nakamichi, S. Nakao, Y. Masuo, 2020, Current Molecular Pharmacology.

Role of organic cation/carnitine transporter 1 in uptake of phenformin and inhibitory effect on complex I respiration in mitochondria.

N. Nakamichi, Y. Kato, Y. Shitara, 2013, Toxicological sciences : an official journal of the Society of Toxicology.

Usefulness of kidney slices for functional analysis of apical reabsorptive transporters

H. Arakawa, T. Nakanishi, N. Nakamichi, 2017, Scientific Reports.

Population Pharmacokinetics of Teicoplanin and Its Dosing Recommendations for Neutropenic Patients With Augmented Renal Clearance for Hematological Malignancies

Y. Kato, Y. Matsuda, K. Ikawa, 2021, Therapeutic drug monitoring.

Coculture with hiPS-derived intestinal cells enhanced human hepatocyte functions in a pneumatic-pressure-driven two-organ microphysiological system

H. Kimura, Y. Sakai, H. Arakawa, 2021, Scientific Reports.

Characterization of the transport of a cationic octapeptide, octreotide, in rat bile canalicular membrane: possible involvement of P-glycoprotein.

H. Kusuhara, Y. Sugiyama, Y. Kato, 1998, Biological & pharmaceutical bulletin.

Ergothioneine-induced neuronal differentiation is mediated through activation of S6K1 and neurotrophin 4/5-TrkB signaling in murine neural stem cells.

N. Nakamichi, Y. Masuo, Y. Kato, 2019, Cellular signalling.

Quantitative Prediction of Drug Interation Involving Metabolism and Transport in the Liver

Y. Sugiyama, Kiyomi Ito, Y. Kato, 2000 .

Mechanism of the upregulation of erythropoietin-induced uptake clearance by the spleen.

Y. Sugiyama, Y. Kato, M. Kato, 1999, American journal of physiology. Endocrinology and metabolism.

erythropoietin-induced uptake clearance by the spleen Mechanism of the upregulation of

Y. Sugiyama, J. Widness, R. Hohl, 2005 .

Immunological response to repeated administration of recombinant human erythropoietin in rats: biphasic effect on its pharmacokinetics.

Y. Kato, K. Kumaki, H. Kamiyama, 1997, Drug metabolism and disposition: the biological fate of chemicals.

Investigation of 5‐FU disposition after oral administration of capecitabine, a triple‐prodrug of 5‐FU, using a physiologically based pharmacokinetic model in a human cancer xenograft model: comparison of the simulated 5‐FU exposures in the tumour tissue between human and xenograft model

H. Ishitsuka, Y. Sugiyama, Y. Tsukamoto, 2001, Biopharmaceutics & drug disposition.

Binding, internalization, degradation, and mitogenic effect of epidermal growth factor in cultured rat hepatocytes

Y. Sugiyama, Y. Kato, 1993 .

Emerging Roles of Uremic Toxins and Inflammatory Cytokines in the Alteration of Hepatic Drug Disposition in Patients with Kidney Dysfunction.

H. Arakawa, Y. Kato, 2023, Drug metabolism and disposition: the biological fate of chemicals.

Renal pharmacokinetic adaptation to cholestasis causes increased nephrotoxic drug accumulation by Mrp6 downregulation in mice.

H. Arakawa, M. Sugimoto, Y. Kato, 2023, Journal of pharmaceutical sciences.

Delivery of Drugs and Antisense Oligonucleotides to the Proximal Tubular Cell of the Kidney Using Macromolecular and Pro‐drug Approaches

Y. Sugiyama, D. Meijer, Y. Kato, 2001 .

A mutation in SLC22A4 encoding an organic cation transporter expressed in the cochlea strial endothelium causes human recessive non-syndromic hearing loss DFNB60

M. Tekin, X. Liu, D. Yan, 2016, Human Genetics.

Binding and transport of methotrexate and its derivative, MX‐68, across the brush‐border membrane in rat kidney

Y. Sugiyama, Y. Kato, Yong‐Hae Han, 1999, Biopharmaceutics & drug disposition.

Species Difference in Intestinal Absorption Mechanism of Etoposide and Digoxin between Cynomolgus Monkey and Rat

Y. Kato, A. Tsuji, N. Amano, 2008, Pharmaceutical Research.

H. Ishitsuka, Y. Sugiyama, Y. Tsukamoto, 2001, Biopharmaceutics & drug disposition.

A Kinetic Pump Integrated Microfluidic Plate (KIM-Plate) with High Usability for Cell Culture-Based Multiorgan Microphysiological Systems

H. Kimura, Y. Sakai, H. Arakawa, 2021, Micromachines.

Ligand-induced downregulation of receptor-mediated clearance of hepatocyte growth factor in rats.

Y. Sugiyama, Y. Kato, K. X. Liu, 1998, The American journal of physiology.

PDZ adaptors: their regulation of epithelial transporters and involvement in human diseases.

Y. Kato, T. Sugiura, T. Shimizu, 2011, Journal of pharmaceutical sciences.

Heparin‐hepatocyte growth factor complex with low plasma clearance and retained hepatocyte proliferating activity

Y. Sugiyama, Y. Kato, Toshikazu Nakamura, 1994, Hepatology.

Effect of knockdown of ezrin, radixin, and moesin on P-glycoprotein function in HepG2 cells.

Y. Kato, T. Ogihara, K. Morimoto, 2011, Journal of pharmaceutical sciences.

Distinct alterations in ATP-binding cassette transporter expression in liver, kidney, small intestine, and brain in adjuvant-induced arthritic rats.

Y. Kato, M. Iwaki, A. Kawase, 2014, Journal of pharmaceutical sciences.

Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes

A. Takahashi, N. Hamajima, N. Shinomiya, 2015, Annals of the rheumatic diseases.

Elucidation of N 1 -methyladenosine as a Potential Surrogate Biomarker for Drug Interaction Studies Involving Renal Organic Cation Transporters s

K. Maeda, H. Kusuhara, Y. Kato, 2019 .

Investigation of the Role of Oligopeptide Transporter PEPT1 and Sodium/Glucose Cotransporter SGLT1 in Intestinal Absorption of Their Substrates Using Small GTP-Binding Protein Rab8-Null Mice

A. Harada, Y. Kato, A. Tsuji, 2009, Drug Metabolism and Disposition.

Interaction of Novel Platelet-Increasing Agent Eltrombopag with Rosuvastatin via Breast Cancer Resistance Protein in Humans

N. Nakamichi, Y. Masuo, Y. Kato, 2014, Drug Metabolism and Disposition.

Fundamental Toxicological Sciences

H. Arakawa, Y. Kato, M. Nishikawa, 2022 .

A Novel Drug Delivery System of Hepatocyte Growth Factor (HGF): Utilization of Heparin-HGF Complex

Y. Sugiyama, T. Terasaki, Y. Kato, 1996 .

Ligand-induced downregulation of receptor-mediated clearance of hepatocyte growth factor in rats.

Y. Sugiyama, Y. Kato, Toshikazu Nakamura, 1998, American journal of physiology. Endocrinology and metabolism.

l-Type amino acid transporter 1 in hypothalamic neurons in mice maintains energy and bone homeostasis

K. Kaneda, Y. Ishigaki, Y. Masuo, 2023, JCI insight.

Combinational therapy with antibiotics and antibiotic-loaded adipose-derived stem cells reduce abscess formation in implant-related infection in rats

H. Arakawa, N. Sugimoto, H. Tsuchiya, 2020, Scientific Reports.

Renal handling of biphosphonate alendronate in rats

Y. Sugiyama, Y. Kato, I. Kino, 1999, Biopharmaceutics & drug disposition.

Organic cation/carnitine transporter OCTN2 (Slc22a5) is responsible for carnitine transport across apical membranes of small intestinal epithelial cells in mouse.

Y. Kato, Y. Sai, I. Tamai, 2006 .